{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124514","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.145775+00:00","generated_at":"2026-05-30T02:15:30.498619+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nuvalent reports Q3 net loss $84.3M; cash $1.2B; pipeline on track for 2025 pivotal data","bullets":["Net loss $84.3M for Q3 2024; R&D expenses $60.6M, G&A $15.8M.","Cash, cash equivalents and marketable securities $1.2B, expected to fund operations into 2028.","Zidesamtinib (ROS1+) Phase 1 data at ESMO; Phase 2 enrollment ongoing (227 patients), pivotal data expected 2025.","NVL-655 (ALK+) Phase 2 enrollment ongoing (229 patients); ALKAZAR Phase 3 trial to start H1 2025.","Appointed Dr. Alice Shaw to Scientific Advisory Board; upsized public offering raised $575M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124514","json":"https://secwatch.observer/filing/0000950170-24-124514.json","markdown":"https://secwatch.observer/filing/0000950170-24-124514.md","text":"https://secwatch.observer/filing/0000950170-24-124514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024124514/0000950170-24-124514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024124514/nuvl-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:15:30.498619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}